hotspot -WSS

hotspot

author：focus 2025-10-01 00:06:59 - browse：76133

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Cigna wins case to block Amy Bricker's move to CVS

focus

WSS

Tuberculosis patients need more than just free medication

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Health care court cases: Humana, Sutter, Novant

California wildfire smoke linked to 52,000 early deaths, study says

Doctors push to include dialysis machines in emergency stockpile

How faith leaders like me can help address America's obesity epidemic

focus

hotspot

focus

Psychedelics group wrestles with new pharma identity

Slovenia has suffered its worst

New air purifier tech could be key to improving indoor air quality

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

23andMe had bad news about my health. I wish a person had delivered it

Medical device trials still don't enroll enough women, study finds

Wildfire smoke exposes gaps in outdoor worker protections

New report analyzes digital physical therapy solutions' effectiveness

Wildfire smoke exposes gaps in outdoor worker protections

How CRISPR works, explained in two minutes

explore

Slovenia has suffered its worst

Report captures long Covid’s disabling effects and policy challenges

Election results set back Medicaid expansion plans

NIH tests clinical research in primary care with $30 million program

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Slovenia has suffered its worst

entertainment

focus

knowledge

leisure time